{"title":"Efficacy of treating allergic dermatoses with the original drug of topical mometasone furoate in standard clinical practice","authors":"K.M. Khobzei, O.B. Tymkiv","doi":"10.30978/ujdvk2023-4-51","DOIUrl":null,"url":null,"abstract":"Skin allergic dermatoses represent a significant issue and account for one of the commonest causes for patients seeking consultations with dermatologists. The prevalence of atopic dermatitis (AD) in the general population reaches 10 % among adults and 20 % among children. Despite the significant deepening of our understanding of the complex pathogenesis of allergic dermatoses and the establishing role of many genetic and epigenetic factors in provoking exacerbations of AD or predisposition to the development of allergic contact dermatitis (ACD), topical corticosteroids remain the cornerstone treatment for flareups of these disorders.We investigated the effectiveness of the mometasone furoate 0.1 % topical cream (Elocom®) for the treatment of patients with allergic dermatoses. The study included 20 patients whose participation was determined based on clinical anamnesis and examination, diagnosed with AD (n = 13) and ACD (n = 7). The duration of treatment was from 7 to 30 days. During the study, all the 20 patients (100 %) noted a significant improvement in the skin condition, 18 (90 %) — improvement during the first days of treatment. Throughout the study, none of the patients experienced side effects linked to the use of the medication. The average value of the Dermatology Life Quality Index among patients before the start of treatment was (13.0 ± 6.83) points, after treatment — (4.8 ± 3.56) points. A decrease in the Index by an average of 8.2 points indicates a significant improvement in the patients’ quality of life. The obtained results demonstrate the high effectiveness of topical mometasone furoate in the treatment of patients with allergic dermatoses. Since these results were obtained in the process of observational research, they have significant practical value.Thus Elokom®, a topical mometasone furoate preparation, is advisable for the treatment of allergic dermatoses in routine clinical practice.","PeriodicalId":23420,"journal":{"name":"Ukrainian Journal of Dermatology, Venerology, Cosmetology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ukrainian Journal of Dermatology, Venerology, Cosmetology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30978/ujdvk2023-4-51","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Skin allergic dermatoses represent a significant issue and account for one of the commonest causes for patients seeking consultations with dermatologists. The prevalence of atopic dermatitis (AD) in the general population reaches 10 % among adults and 20 % among children. Despite the significant deepening of our understanding of the complex pathogenesis of allergic dermatoses and the establishing role of many genetic and epigenetic factors in provoking exacerbations of AD or predisposition to the development of allergic contact dermatitis (ACD), topical corticosteroids remain the cornerstone treatment for flareups of these disorders.We investigated the effectiveness of the mometasone furoate 0.1 % topical cream (Elocom®) for the treatment of patients with allergic dermatoses. The study included 20 patients whose participation was determined based on clinical anamnesis and examination, diagnosed with AD (n = 13) and ACD (n = 7). The duration of treatment was from 7 to 30 days. During the study, all the 20 patients (100 %) noted a significant improvement in the skin condition, 18 (90 %) — improvement during the first days of treatment. Throughout the study, none of the patients experienced side effects linked to the use of the medication. The average value of the Dermatology Life Quality Index among patients before the start of treatment was (13.0 ± 6.83) points, after treatment — (4.8 ± 3.56) points. A decrease in the Index by an average of 8.2 points indicates a significant improvement in the patients’ quality of life. The obtained results demonstrate the high effectiveness of topical mometasone furoate in the treatment of patients with allergic dermatoses. Since these results were obtained in the process of observational research, they have significant practical value.Thus Elokom®, a topical mometasone furoate preparation, is advisable for the treatment of allergic dermatoses in routine clinical practice.